Acasti Pharma Inc. (NASDAQ:ACST) Q1 2020 Earnings Conference Call - Final Transcript

Aug 14, 2019 • 01:00 pm ET


Acasti Pharma Inc. (NASDAQ:ACST) Q1 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good day, ladies and gentlemen, and thank you all for joining us for this Acasti Pharma First Quarter 2020 Earnings Conference Call. As a reminder, all lines have been placed in a listen-only mode. And after today's prepared remarks, you will have the opportunity to ask questions. Also a reminder, today's webinar is being recorded. [Operator Instructions].

And now to get us started with opening remarks and introductions, I am pleased to turn the floor to David Waldman, Investor Relations for Acasti Pharma. Welcome, David.

Ladies and gentlemen, I do apologize for the delay and I believe we may have lost connection with our primary speaker site. Please standby one the line one moment while we attempt to reconnect. And Ladies and gentlemen, this is your operator, Jim. Please standby on the line while we attempt to reconnect. Ladies and gentleman, thank you all for your patience. David, please go ahead. Your audience is listening.

David Waldman

Thank You. Good afternoon, everyone, and welcome to Acasti Pharma's first quarter fiscal 2020 conference call. On the call with us this afternoon are Jan D' Alvise, President and CEO; Pierre Lemieux, Chief Operating Officer, Chief Scientific Officer and Co-Founder; Brian Groch, Chief Commercial Officer; and Jean-Francois Boily, Vice President of Finance. If you have any questions after the call or would like any additional information about the company, please contact Crescendo Communications at (212) 671-1020.

I'd also like to remind everyone that statements on this conference call that are not statements of historical or current facts constitute forward-looking information within the meaning of the Canadian securities laws and forward-looking statements within the meaning of U.S. federal securities laws. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider -- statements labeled with the terms believes, belief, excepts, intend, anticipates, potential, should, may, will, plans, continue or other similar expressions to be uncertain and forward-looking. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call.

Forward-looking statements in this conference call include but are not limited to information or statements about Acasti's strategy, future operations, prospects and the plans of management. Acasti's ability conduct all required clinical and nonclinical trials for CaPre, including the timing and results of those trials; the timing and the outcome of licensing negotiations; CaPre's potential to become the best-in-class cardiovascular drug for treating hypertriglyceridemia; CaPre's potential to meet or exceed the target primary endpoint; Acasti's ability to commercially launch CaPre; and Acasti's ability to fund its continued operations.

The forward-looking statements contained in this conference call are expressly qualified in their entirety by this cautionary statement. The Cautionary Note Regarding Forward-Looking Information section contained in Acasti's latest annual report on Form 20-F